Status:
COMPLETED
Local, Non-Interventional Study of RoActemra (Tocilizumab) in Poland (ACT-POL): First-Line Treatment in Routine Clinical Practice of Participants With Rheumatoid Arthritis (RA)
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this non-interventional, prospective, observational study is to assess the effectiveness and tolerability of RoActemra (tocilizumab) used as a first-line biologic treatment in participants ...
Eligibility Criteria
Inclusion
- participants at least 18 years of age
- a diagnosis of moderate to severe RA
- treating physician has made the decision to commence tocilizumab in first line biologic treatment (population of DMARDs inadequate responders or participants who are intolerant to DMARDs) in a routine clinical practice in Poland
- informed consent
Exclusion
- N/A
Key Trial Info
Start Date :
August 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2016
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT02234960
Start Date
August 1 2014
End Date
July 1 2016
Last Update
November 2 2016
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Bydgoszcz, Poland, 85-168
2
Bydgoszcz, Poland, 85-681
3
Bytom, Poland, 41-902
4
Gmina Śrem, Poland, 63-100